OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Comparative Effectiveness Research is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Journal of Comparative Effectiveness Research : 2022 year in review	51
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary	41
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis	41
Access in all areas? A round-up of developments in market access and health technology assessment: part 10	36
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database	35
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis	32
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis	30
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy	27
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea	27
Ataluren for the treatment of people living with nonsense mutation Duchenne muscular dystrophy: a plain language summary of Study 041	23
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis	23
Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison	23
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies	22
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20	21
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study	20
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims	18
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis	18
Access in all areas? A round-up of developments in market access and health technology assessment: first Joint Clinical Assessment report released	18
Considerations for assessing the feasibility of network meta-analysis of seasonal vaccines	17
Effect of dose tapering policy on the prescription of advanced therapy for rheumatoid arthritis: a retrospective analysis of clinical and cost outcomes in Taiwan	16
Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review	16
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience	15
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity	14
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer	14
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA	13

Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD	13
Healthcare utilization and costs following molecular diagnostic testing among patients with vaginitis	13
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?	13
Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies	13
Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis	12
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China	12
Economic evaluation of stapokibart for chronic rhinosinusitis with nasal polyps in China: a cost–effectiveness analysis	12
Corrigendum	12
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases	12
Comparison of two-stage methods for count data in Mendelian randomization: a simulation study	11
Access in all areas? A round-up of developments in market access and health technology assessment: part 11	11
Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients	11
Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab	11
Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China	11
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer	11
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	11
A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis	11
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations	11
Impact of lymph node dissection on overall survival and cancer-specific survival in elderly patients with early-stage non-small cell lung cancer: a SEER database analysis	10
Real-world comparative effectiveness of analogue and human insulin on glycemic control in children and adolescents with Type 1 diabetes in Lebanon using continuous glucose monitoring data	10
Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol	10
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	10
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada	10
Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy	10
Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practic	10
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer	10
Cost–effectiveness of lung cancer screening with volume computed tomography in Portugal	10
Acceptability of external control-arm use in nononcology health technology assessment submissions	10
Diversity in clinical trial inclusion for peripheral artery disease lower extremity endovascular interventions: a systematic review protocol	10
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors	10
COVID-19 clinical trials: who is likely to participate and why?	9
Comparison of Enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study	9
Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome	9
Characterization of medical device randomized controlled trials with adaptive designs	9
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma	9
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies	9
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care	8
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10	8
Access in all areas? A round up of developments in market access and health technology assessment: part 1	8
Corrigendum	8
Tr14 gel for the treatment of acute ankle sprains: a plain language summary of the TRAUMED trial	8
The effects of Pilates on pain, functionality, quality of life, flexibility and endurance in lumbar disc herniation	8
Rivaroxaban versus low-molecular-weight heparins for short- and long-term prognosis in patients with deep vein thrombosis after spontaneous intracranial hemorrhage	8
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications	7
Composite endpoints in health technology assessment: Part 1 – an illustration of best modeling practice	7
Navigating adalimumab biosimilars: an expert opinion	7
Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US	7
Treatment goals for rheumatoid arthritis: patient engagement and goal collection	7
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma	7
Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospec	7

Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma	7
Efficacy of selpercatinib as a first-line treatment for RET -fusion positive non-small-cell lung cancer: a novel two-stage Bayesian network meta-analysis	7
Quality in qualitative evidence: new best practice principles from NICE’s real-world evidence framework	7
A value-based budget impact model for dronedarone compared with other rhythm control strategies	7
Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization	7
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers	7
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison	7
Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease	7
Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary	7
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD	6
Use of transportability methods for real-world evidence generation: a review of current applications	6
The inaugural HEMA report: a missed opportunity for comprehensive value assessment	6
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15	6
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design	6
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant	6
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions	6
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US	6
In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database	6
The value of time savings in breast cancer therapy for patients and healthcare providers: the subcutaneous injection of pertuzumab and trastuzumab fixed-dose combination at a tertiary care center in t	6
The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives	6
Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation	6
Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal: insights from a Portuguese Delphi Consensus	6
Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses	6
Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data	6
The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada	6
Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race/ethnicity	6
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study	6
QDOT MICRO™ versus THERMOCOOL ^® SMARTTOUCH™ and THERMOCOOL SMARTTOUCH ^® Surround Flow in radiofrequency ablation of paroxysmal atr	6
Expanding the learning health system model to be health literate	6
Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Mexico: a systematic review	6
Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China	6
Clinical and economic burden among older adults with acromegaly in the United States	6
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling	6
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges	6
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting	5
Resource utilization and economic outcomes following repetitive transcranial magnetic stimulation for treatment-resistant depression: a retrospective observational analysis	5
Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here	5
Impact analysis of expanded access to ketamine for treatment-resistant depression	5
Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs	5
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis	5
Visualizing the target estimand in comparative effectiveness studies with multiple treatments	5
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data	5
Advancing real-world evidence harmonization: lessons from the UK, EMA and global policy frameworks	5
Val (EU) xit: do we need an international ISPOR value flower?	5
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib	5
How pharma can amplify product value with implementation science	5
Real-world clinical outcomes of patients with localized prostate cancer treated with radical prostatectomy in SEER-Medicare	5
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study	5
An international observational study assessing conservative management in hemorrhoidal disease: results of CHORALIS (aCute HemORrhoidal disease evALuation International Study)	5
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis	5
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis	5
The need to consider market access for pharmaceutical investment decisions: a primer	5
Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study	5
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants	5
Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial	5
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	5
Budget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion™ 2 in Canada and Italy	5